The introduction of newer antihyperglycemic agents, including GLP-1 RAs and SGLT2 inhibitors, has increasingly expanded the opportunities for improving clinical outcomes in patients with type 2 diabetes.1
This program supports primary care physicians in navigating the changing diabetes landscape beyond glycemic control.
The efficacy and clinical evidence of antihyperglycemic agents in lowering blood glucose and providing cardiovascular protection will be illustrated through case-based learning, with the goal of increasing clinicians’ confidence in adjusting or advancing therapy according to the most recent recommendations from Diabetes Canada.
This program has been developed in collaboration with M3 (EU) Ltd.
This program has received an education grant or in-kind support from Novo Nordisk.